AAMC is in the process of treating its first patient using the cutting edge technology of the NOVOTTF-100A, a portable device delivering low intensity, intermediate frequency electric fields via non-invasive transducer rays. Tumor Treatment Fields, a completely new therapeutic modality in cancer treatments, physically interferes with cell division. The FDA has approved this device for use in recurrent glioblastoma after standard therapies have failed. The treatment device appears comparable to second line chemotherapy regimens that are commonly used, but toxicity and quality of life appear more favorable with TTF. Click here to read clinical article.